Non Invasive Prenatal Testing (NIPT) Market Growth, and Share from 2019 to 2027
Posted by Savi Bnagar on December 27th, 2019
Meticulous Research®– leading global market research company published a research report titled “Non Invasive Prenatal Testing (NIPT) Market by Product (Consumables, NGS, Ultrasound, Microarray, PCR), Method (Ultrasound Screening, Cell Free DNA Test), Application (Trisomy, Sex Chromosome Abnormalities), & End User – Forecast to 2027”.
According to this latest publication from Meticulous Research®, the Global Non-Invasive Prenatal Testing Market is expected to grow at a CAGR of 17.1% from 2019 to exceed .6 billion by 2027.
The high growth of non-invasive prenatal testing market is mainly attributed to the high risk of chromosomal abnormalities with increasing maternal age, rise in occurrences of chromosomal aneuploidies among fetus, development of advanced and new technologies and non-invasive parenteral testing products, and improving reimbursement scenario for NIPT. Rising awareness regarding non-invasive prenatal testing and untapped market opportunity in emerging markets offer significant growth opportunities for the players operating in this market. However, strict regulatory guidelines and ethical hurdles are some of the key factors challenging the adoption of non-invasive prenatal testing products over the coming years.
Growth prospects in NIPT market
The global non-invasive prenatal testing market study presents historical market data in terms of values (2017 and 2018), estimated current data (2019), and forecasts for 2027-by product and solutions (consumables, instruments, software, services), method (ultrasound detection, biochemical screening tests, cellfree DNA in maternal plasma tests), application (trisomy, microdeletion syndrome, others), and end users. The study also evaluates industry competitors and analyzes the market at a regional and country level.
On the basis of products and solutions, the NIPT services segment is expected to grow at the fastest CAGR during the forecast period. The highest CAGR of this segment is mainly attributed to factors such as rising incidence of genetic disorders, increasing focus on prenatal screening, and government initiatives to provide prenatal testing services.
On the basis of application, trisomy segment is estimated to account for the largest share of the overall NIPT market in 2019. The large share of this segment is mainly attributed to the factors such as increasing maternal age and rising incidence of chromosomal abnormalities.
On the basis of end user, diagnostic laboratories segment is estimated to account for the largest share of the overall NIPT market in 2019, due to large volume of NIPT testing done at diagnostic laboratories owing to availability of the well-equipped facility and trained/skilled laboratory technicians. The initiatives taken by diagnostic laboratories to provide high quality testing services is driving the growth in this market.
This research report analyzes major geographies and provides comprehensive analysis for North America (U.S., Canada), Europe (Germany, France, the U.K., Italy, Spain, and Rest of Europe), Asia-Pacific (Japan, China, India, and RoAPAC), Latin America, and Middle East & Africa. North America commanded the largest share of the global non-invasive prenatal testing market, followed by Europe and Asia-Pacific. High diagnostic and treatment rate of trisomy disorders and the emergence of key organizations in the U.S. are accelerating the non-invasive prenatal testing market in the North American region. However, Asia Pacific region is expected to grow at the highest CAGR during the forecast period due to developing healthcare infrastructure, rising focus of prominent players on expanding their presence in Asia, and rising awareness programs & conferences.
The key players operating in the global non-invasive prenatal testing market are Agilent Technologies, Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), PerkinElmer, Inc. (U.S.), Illumina, Inc. (U.S.), Beijing Genomics Institute (China), Eurofins LifeCodexx AG (Germany), NATERA, INC. (U.S.), Igenomix SL (Spain), Laboratory Corporation of America Holdings (U.S.), F. Hoffman-La Roche Ltd. (Switzerland), GE Healthcare (U.S.), and Yourgene Health (U.K.) among others.
Key questions answered in the report-
Get Sample Pages with TOC @ https://www.meticulousresearch.com/request-sample-report/cp_id=5068
Contact Sales- +1-646-781-8004
Like it? Share it!
About the AuthorSavi Bnagar
Joined: September 17th, 2019
Articles Posted: 11
More by this author